Neuritek Therapeutics Secures 25 Million EUR Capital Commitment

Neuritek Therapeutics, a biotech company, announced that it has signed an agreement with GEM Global Yield to provide Neuritek with up to EUR 25 million over a 3 year term following a public listing of Neuritek common stock. Neuritek will use the funds to develop treatments for posttraumatic stress disorder (PTSD), a medical condition that frequently develops in people after exposure to severe trauma.